Intravenous (IV) Ibuprofen Market To See Record Break Revenue $14.2 Million By 2022 | Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc.

UPDATE AVAILABLE ON-DEMAND

According to the research report published by Allied Market Research, the global Intravenous (IV) Ibuprofen market is expected to register a CAGR of 20.0% from 2016 to 2022. The research includes changing market dynamics, top impacting factors, key investment pockets, value chain, and competitive scenario. Through tabular and graphical representation, the report offers key insights on different aspects of the market such as current market size and estimations, region-wise analysis, and opportunities. Porter’s Five Forces analysis has been mentioned in the report to outline competitive intensity. The report is a helpful source of information to unlock potential from emerging countries and expand businesses to gain international presence.

The pain indication segment accounted for over three-fourths share in 2015 and is expected to maintain its dominance throughout the forecast period.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/1387

The major factors that boost the market growth include, increase in adoption of an intravenous mode of drug delivery for acute pain management due to faster onset of action as compared to the other routes (oral and transdermal mode of administration) and targeted drug delivery property.

The market growth is further augmented as IV ibuprofen improves pain management with less dependence on opioid analgesic medication, which may lead to several health complications such as sedation, dizziness, and others. Caldolor (Cumberland Pharmaceuticals) is the only injectable ibuprofen drug available in the market; hence, it has huge demand with minimal competition. However, numerous factors are likely to restrain the market growth such as lengthy approval process and limited geographic (country specific) approvals.

The U.S. is anticipated to remain the highest revenue-generating region during the forecast period, owing to the widespread adoption of IV Ibuprofen for treating pain and fever. However, Australia is expected to grow rapidly during the forecast period, owing to recent entry of IV Ibuprofen in this market, increasing awareness of non-steroidal anti-inflammatory drugs, and shifting trend towards intravenous mode of drug delivery.

Inquire Before Buying @ https://www.alliedmarketresearch.com/purchase-enquiry/1387

The IV Ibuprofen market is dominated by Cumberland Pharmaceuticals and is actively engaged in research for the development of novel IV Ibuprofen products

The Major Key Players Are:

• Cumberland Pharmaceuticals Inc.
• Alveda Pharmaceuticals, Inc.
• (Acquired by Teligent, Inc.)
• CSL Limited
• Sandor Medicaids Pvt. Ltd.
• PT. Soho Industri Pharmasi
• Germin MED
• Grifols S.A.
• Harbin Gloria Pharmaceuticals Co., Ltd.
• Al Nabeel International Ltd.
• Laboratorios Valmorca, C.A.

Key Findings of IV Ibuprofen Market:

• Fever is projected to be the fastest growing indication segment.
• Australia IV Ibuprofen market is expected to grow at the fastest CAGR of 14.7% from 2015 to 2020.
• In 2015, the U.S. and Canada collectively accounted for more than three-fourths of the global IV Ibuprofen market.

Access Full Report @ https://www.alliedmarketresearch.com/Intravenous-Ibuprofen-market

Contact:

David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.